That's because it is expected that data from it will be released in Q4 of 2023. If the endpoint is met, then Sarepta will likely be able to receive approval of a label expansion. Having said that, it has already moved on to initiate a study known as ENVISION [study-303], which is using ELEVIDYS to target this non-ambulatory DMD patient population. Currently, the analyst consensus on Crinetics Pharmaceuticals is https://1investing.in/ a Strong Buy with an average price target of $49.13, representing a 60.6% upside. In a report issued on August 30, Oppenheimer also initiated coverage with a Buy rating on the stock with a $40.00 price target. Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enou...
Its platform facilitated about 10% of U.S. e-commerce sales in terms of gross merchandise volume as of the end of 2022. A business that has done so once with Shopify's platform is unlikely to want to switch providers and then have to do that work all over again. Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers and Stephen Mayo. 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer. Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Food and Drug Administration has indicated after talks with the company that it's working toward granting accelerated approval of SR...
This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The U.S. Food and Drug Administration has deferred its decision on an accelerated approval for Sarepta Therapeutics Inc's gene therapy for a muscle wasting disorder called Duchenne muscular dystrophy ... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the FDA approval of ELEVIDYS, the first gene therapy approved to treat Duchenne muscular dystrophy. Food and Drug Administration approval of the first gene therapy for children with Duchenne muscular dystrophy, was downgr... The $3.2 million one-time treatment is the first gene therapy approved to treat DMD, a progressive and fatal condition that manifests in early childhood. For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.
Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. • Regarding VRTX VRTX, we observe a put option sweep with bearish sentiment.
I believe that such expansion can be further bolstered with the two ways it can expand its label, as I mentioned above. The conclusion is that Sarepta Therapeutics has done well to advance ELEVIDYS for the treatment of ambulatory patients ages 4 and 5. There are two ways to expand its label for this gene therapy as I stated before. If both ways are achieved, then it will have the ability to target up to 95% of the entire DMD patient population. As I noted above, it is expected that the global DMD indication will be a multi-billion dollar market.
According to the 10-Q SEC Filing, Sarepta Therapeutics had cash, cash equivalents, investments and long-term restricted cash of $1.9 billion as of June 30, 2023. This pharma company though has already received prior regulatory approvals for three DMD-targeted drugs which are EXONDYS 51, AMONDYS 45 and VYONDYS 53. Thus, the company generates net product revenues for these approved gaap in india drugs. For the 3 months ending June 30, 2023, it was noted that net product revenues of $239 million were achieved. This, compared to the same time period the year before where net product revenues only reached $211.2 million. Sales of ELEVIDYS were not achieved during the most recently reported quarter, but this is another way Sarepta can generate revenues from the DMD market.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 36.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation.
Posted: Tue, 22 Aug 2023 07:00:00 GMT [source]
The primary endpoint of this study is going to be the change in North Star Ambulatory Assessment [NSAA] total score from baseline up until week 52. This leads to the next possible way for Sarepta to expand its label for ELEVIDYS and that would be through the targeting of non-ambulatory DMD patients. On June 22nd, 2023, Sarepta Therapeutics announced that the FDA had granted it Accelerated Approval of ELEVIDYS for ambulatory Duchenne Muscular Dystrophy [DMD] patients ages 4 and 5. However, as I noted above, there are two ways where it might be able to expand its label to possibly treat up to 95% of the entire DMD patient population. If it ultimately achieves this goal, then it can expect to target a huge chunk of the market with its gene therapy ELEVIDYS. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vigil Neuroscience Inc today and set a price target of $24.00.
Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. There are several risks that investors should consider before investing in Sarepta Therapeutics.
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I believe that the release of results from the pivotal EMBARK study in Q4 of 2023 is going to be the first critical part of expanding the label. Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $183.14.
The third and final risk to consider would be the cost of ELEVIDYS. While this gene therapy holds great potential, it is set to be sold for $3.2 million for a treatment. The risk here is that there is no assurance that ELEVIDYS will do well on the market with this list price.
The total cost received by the writing party (or parties) was $29.7K, with a price of $805.0 per contract. There were 1931 open contracts at this strike prior to today, and today 212 contract(s) were bought and sold. • Regarding SYK SYK, we observe a call option sweep with bearish sentiment. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $600.0 per contract. There were 492 open contracts at this strike prior to today, and today 309 contract(s) were bought and sold.
The decision marks the first approval of a gene therapy to treat DMD, a fatal and progressive disease that manifests in young children. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.
The total cost received by the writing party (or parties) was $145.7K, with a price of $2470.0 per contract. There were 268 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. • Regarding MRNA MRNA, we observe a call option sweep with bullish sentiment. This particular call needed to be split into 9 different trades to become filled.
See which 3 stocks are most likely to make moves following their insider activities. The company is already delivering solid financial results, at least on the top line. In the second quarter, Shopify's revenue increased by 31% year over year to $1.7 billion. Shopify remained unprofitable with a net loss per share of $1.02, slightly worse than the $0.95 reported in the year-ago period. Despite the persistent red ink on the bottom line, Shopify remains an excellent long-term bet. For those who are focused on the long game, that would likely be money well spent.
The total cost received by the writing party (or parties) was $45.3K, with a price of $605.0 per contract. There were 1215 open contracts at this strike prior to today, and today 75 contract(s) were bought and sold. • For JNJ JNJ, we notice a put option sweep that happens to be neutral, expiring in 36 day(s) on October 20, 2023. This event was a transfer of 100 contract(s) at a $165.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $30.7K, with a price of $307.0 per contract.
The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder, but is expected to cost millions of dollars. Doug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get r... We’d like to share more about how we work and what drives our day-to-day business.